A new pharmaceutical candidate enters Lundbeck's development pipeline
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) strengthens its pipeline of pharmaceuticals in clinical development by initiating clinical phase I studies with Lu AF11167 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans.
Merck and Its Employees to Donate to Japanese Relief Effort
- Details
- Category: Merck Group
Merck KGaA announced that in order to provide assistance to the Japanese people following the earthquake and tsunami that devastated parts of their country, the company will donate a total of 100 million YEN (approximately EUR 875,000).
UK and US governments reach agreement over AstraZeneca tax matters
- Details
- Category: AstraZeneca
AstraZeneca has been informed that the UK and US governments' tax authorities have agreed to the terms of an Advance Pricing Agreement regarding transfer pricing arrangements for AstraZeneca's US business for the 13-year period from 2002 to the end of 2014.
GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that it will no longer pursue global approval (marketing authorisation) for the use of Avodart™ (dutasteride) to reduce the risk of prostate cancer.
Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China
- Details
- Category: Novartis
Novartis completed the transaction to acquire an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. This acquisition provides Novartis with an expanded presence in the Chinese vaccines market
Sanofi-aventis Strengthens Commitment to Ophthalmology through Partnership with The Vision Institute
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the official signing of a cooperation agreement between Fovea Pharmaceuticals, its Ophthalmology Division, and the Vision Institute, one of the main eye disease research centers in Europe, for research in the diagnosis, prevention and treatment of ocular diseases.
SPIRIVA HandiHaler Prolonged Time To First COPD Exacerbation
- Details
- Category: Pfizer
A new study showed that SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder), a long-acting anticholinergic, was significantly more effective at preventing Chronic Obstructive Pulmonary Disease (COPD) exacerbations than salmeterol HFA-MDI (hydrofluororalkane-metered dose inhaler).
More Pharma News ...
- Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor
- Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint
- Novartis receives European Commission approval for Gilenya®
- GSK supports recovery efforts to help those affected by the Japan earthquake
- Novartis committed to provide equivalent of more than USD 3 million in relief aid to Japan earthquake victims
- MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim
- NAFE Names Lilly to Top 50 Companies for Executive Women